expressionin cancer tissue has no prognostic impact in non-small cell lung cancer patients

271 G>A polymorphism of the KDR gene is related to transcriptional regulation in patients with non-small cell lung cancer.

Ginsenosides Rg3 can down-regulate the expressions of KDR and VEGF in human lung squamous cancer SK-MES-1 cells.

bronchial washing VEGFR2 levels are correlated to overall survival in non-small cell lung cancer patients

can be used as an independent prognostic biomarker in combination with VEGF-A in advanced non-small-cell lung cancer

RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

Vascular endothelial growth factor receptor 2 gene polymorphisms is associated with tumor recurrence in non-small-cell lung cancer.

blocking the expression of VEGFR2 inhibited proliferation, migration, and invasion in the non-small cell lung cancer cell line Calu-1

Sulfated fucoidan FP08S2 from Sargassum fusiforme blocks VEGFR2/Erk/VEGF signaling to prevent angiogenesis in lung cancer.

Study demonstrated that KDR was downregulated in nonsmall cell lung cancer (NSCLC) specimens. KDR was also found as the target gene for miR497.

SUMOylation of vascular endothelial growth factor receptor 2 inhibits the proliferation, migration, and angiogenesis signaling pathway in non-small cell lung cancer.

Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer.

Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.

Introduction of sVEGFR-2 suppressed lymphangiogenesis in primary lung cancer and also suppressed lymphogenic metastasis by inhibiting VEGF-C, followed by down-regulation of VEGFR-2, VEGFR-3 and MMPs.